Certara
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 209m | 244m | 286m | 336m | 354m | 386m | 427m |
% growth | 27 % | 17 % | 17 % | 17 % | 6 % | 9 % | 11 % |
EBITDA | 60.4m | 17.9m | 58.6m | 89.0m | 70.8m | - | - |
% EBITDA margin | 29 % | 7 % | 20 % | 27 % | 20 % | - | - |
Profit | (8.9m) | (49.4m) | (13.3m) | 14.7m | (55.4m) | - | - |
% profit margin | (4 %) | (20 %) | (5 %) | 4 % | (16 %) | - | - |
R&D budget | 11.6m | 19.6m | 20.4m | 28.2m | 34.2m | - | - |
R&D % of revenue | 6 % | 8 % | 7 % | 8 % | 10 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$850m Valuation: $850m | Buyout | ||
N/A | $668m Valuation: $3.5b 16.8x EV/LTM Revenues 57.9x EV/LTM EBITDA | IPO | |
* | N/A | $140m | Post IPO Equity |
N/A | Grant | ||
* | $449m | Secondary | |
* | N/A | Grant | |
Total Funding | - |
Recent News about Certara
EditCertara is a leading provider of biosimulation and data science solutions aimed at optimizing drug development and regulatory submissions. The company serves pharmaceutical and biotechnology companies, as well as regulatory agencies, by offering a suite of software and consulting services that enhance decision-making throughout the drug development lifecycle. Certara operates in the global healthcare market, focusing on improving the efficiency and success rates of clinical trials and regulatory processes. Its business model revolves around selling software licenses, providing consulting services, and offering training programs. Revenue is generated through a combination of subscription fees, service contracts, and educational courses. Certara's key offerings include biosimulation, data visualization, regulatory submission preparation, market access strategies, and discovery informatics. The company leverages advanced technologies such as deep learning analytics and artificial intelligence to deliver innovative solutions that address complex challenges in drug development.
Keywords: biosimulation, data science, drug development, regulatory submissions, clinical trials, pharmaceutical, biotechnology, software, consulting, AI.